Teriparatide treatment of osteoporosis in solid organ transplant recipients—a single-center experience Authors: Talia Diker Cohen, Ilana Shraga-Slutzky, Keren Kaminer, Alexander Gorshtein, Idit Dotan, Gloria Tsvetov Published: 2026 ABSTRACT SummarySolid organ transplant recipients face high fracture risk with limited evidence guiding anabolic therapy. In this real-world cohort, teriparatide was associated with significant improvements in bone mineral density and acceptable safety without adverse graft effects. These findings support selective anabolic treatment in high-risk transplant recipients and highlight the need for prospective studies.PurposeSolid organ transplant (SOT) recipients are at high risk for osteoporosis and fragility fractures due to pre-existing organ dysfunction and long-term immunosuppressive therapy, particularly glucocorticoids. However, evidence supporting the use of anabolic osteoporosis therapy in this population remains limited.MethodsWe conducted a retrospective cohort study at a large transplant center including adult kidney, lung, and liver transplant recipients selected for teriparatide treatment based on clinical indications for severe post-transplant osteoporosis for at least 3 months. Bone mineral density (BMD), incident fractures, biochemical parameters, renal function, and adverse events were evaluated during treatment and follow-up.ResultsThirty-nine SOT recipients (33% men; mean age 61.3 ± 11.6 years) were included, comprising kidney (n = 10), lung (n = 20), and liver (n = 9) transplant recipients. Prior fragility fractures were present in 90% of patients, and 79% had multiple fractures. Median teriparatide treatment duration was 22.3 months. Significant increases in BMD were observed at the lumbar spine (+11 ± 15%, p = 0.01), femoral neck (+8 ± 14%, p = 0.05), and total hip (+11 ± 16%, p = 0.05). Six patients sustained fractures after teriparatide initiation; only two occurred during active therapy, whereas four occurred after treatment discontinuation. Hypercalcemia occurred in one patient and led to treatment cessation. The estimated glomerular filtration rate declined modestly during the first 6 months and stabilized thereafter; a broadly similar pattern was observed in contemporaneous matched transplant controls. No episodes of graft rejection were observed.ConclusionsIn this real-world cohort of SOT recipients with severe osteoporosis, teriparatide therapy was associated with significant improvements in BMD, acceptable safety, and no apparent excess risk to graft function. These findings support the selective use of anabolic therapy in high-risk transplant recipients and highlight the need for prospective studies to define optimal treatment strategies.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s11657-026-01751-4. Introduction Solid organ transplant (SOT) recipients are at markedly increased risk for osteoporosis and fragility fractures due to pre-existing organ dysfunction, frequent vitamin D deficiency, and chronic immunosuppressive therapy, most notably glucocorticoid-induced osteoporosis [1, 2]. Guidelines for diagnosis and treatment of osteoporosis in transplant patients are available [1], and several were issued specifically for heart [3], kidney [4], and liver [5] transplant recipients but not for lung transplant recipients. However, data on the efficacy and safety of anti-osteoporotic treatment in this population are limited. While bisphosphonates remain the most commonly used agents for prevention and treatment of osteoporosis in this population, their utility is often limited by renal dysfunction, prompting consideration of alternative therapies [6]. Teriparatide is a recombinant parathyroid hormone (PTH) analogue. It is an effective anabolic treatment for osteoporosis in post-menopausal women [7] and men [8], as well as for glucocorticoid-induced osteoporosis [9]. However, its role in SOT recipients is less defined. There has been only one randomized trial on the use of teriparatide in kidney transplant recipients (6 months, 26 patients) [10] and several small case reports and retrospective studies [11–15]; none has shown data about fractures. Purpose The aim of this study was to describe a large transplant center experience in treatment of post-transplant osteoporosis with teriparatide, including efficacy measures (fractures, bone density) and safety measures (hypercalcemia, hypercalciuria, kidney function, graft rejection). Methods Study design and population We conducted a retrospective cohort study using electronic medical records (EMR) at Rabin Medical Center, the largest solid organ transplant center in Israel. The study was approved by the local Helsinki Ethics Committee. Adult SOT recipients (kidney, lung, liver, or heart) who received teriparatide therapy at any time after transplantation for a minimum duration of 3 months were eligible for inclusion. The study population did not represent an unselected transplant cohort but rather a clinically selected subgroup. Initiation and duration of teriparatide therapy were not protocol-driven but reflected routine clinical practice and individualized physician decision-making. Treatment was typically initiated in patients with severe osteoporosis, defined by low bone mineral density and/or prior fragility fractures, particularly in those with inadequate response, intolerance, or contraindications to antiresorptive therapy. In addition, access to teriparatide in Israel is largely regulated through national reimbursement criteria, which preferentially support its use in patients with severe or glucocorticoid-induced osteoporosis. Patients were followed from initiation of teriparatide therapy until treatment discontinuation and subsequent clinical follow-up, when available. Data collection For each eligible patient, electronic medical records were reviewed for demographic characteristics (age and sex), transplanted organ type, body mass index (BMI), and osteoporosis risk factors, including diabetes mellitus, menopausal status, male hypogonadism, and smoking. Data were also collected on prior anti-osteoporotic therapies, bone mineral density (BMD) assessed by dual-energy X-ray absorptiometry (DXA), and history of fragility fractures before and after teriparatide initiation. Treatment duration was determined from prescription records, along with information on calcium and vitamin D supplementation and immunosuppressive therapy, including glucocorticoid use. Bone outcomes Osteoporosis was defined as a BMD T-score ≤ −2.5 standard deviations in at least one skeletal site (lumbar spine, femoral neck, total hip, or distal radius). Changes in BMD were assessed using paired DXA measurements obtained at the initiation and at the end of teriparatide therapy, when available. This approach was chosen to ensure that observed changes corresponded to the treatment period. Incident fractures after teriparatide initiation were identified from clinical documentation and imaging reports. Laboratory assessments Biochemical parameters collected included serum albumin-corrected calcium, serum creatinine, estimated glomerular filtration rate (eGFR), serum 25-hydroxyvitamin D (25(OH)D), and 24-h urine calcium excretion when available. Baseline laboratory values were defined as measurements obtained within 6 months prior to teriparatide initiation. Follow-up laboratory values were collected at predefined time points during therapy, at the end of teriparatide treatment, and at 3–6 months after treatment discontinuation, when available. For each time point, mean stable serum calcium and creatinine values were used for analysis. Hypercalcemia was defined as an albumin-corrected serum calcium concentration > 10.5 mg/dL. Estimated GFR (mL/min/1.73 m2) was calculated using the Modification of Diet in Renal Disease (MDRD) equation [16]. Renal function was assessed longitudinally using serial eGFR measurements. Changes in eGFR over time within the teriparatide-treated cohort were evaluated descriptively and using within-subject statistical comparisons. Clinically significant renal deterioration was defined as a decline in eGFR to < 30 mL/min/1.73 m2 or progression to end-stage kidney disease. For contextual comparison, eGFR trends were descriptively summarized in a contemporaneous cohort of transplant recipients not treated with teriparatide (“control group”). Controls were matched 1:1 to teriparatide-treated patients by sex, age at transplantation, and transplanted organ. For each teriparatide user, the interval between transplantation and initiation of teriparatide was applied to the contemporaneous matched control to define the index date for follow-up. Serum creatinine levels in controls were collected at the index date, 6 months, and 2 years thereafter. The control group was included solely to provide contextual comparison for longitudinal renal function and was not intended for formal comparative analyses of skeletal outcomes or treatment effects. Statistical analysis Descriptive statistics were used to summarize baseline characteristics and outcomes. Continuous variables are presented as mean ± standard deviation or median (range), as appropriate. Categorical variables are presented as number and percentage. Changes in continuous variables over time within individuals were analyzed using paired statistical tests or repeated-measures analysis of variance (ANOVA), as appropriate, accounting for within-subject correlations. Between-group comparisons were performed using independent-sample T tests for continuous variables and chi-square or Fisher’s exact tests for categorical variables. All statistical analyses were performed using Microsoft Excel (version 2511). A two-sided p value < 0.05 was considered statistically significant. Results Baseline characteristics Thirty-nine teriparatide-treated transplant patients were included in the final analysis (10 kidney, 20 lung, 9 liver; although heart transplant recipients were eligible, none met inclusion criteria). Baseline characteristics of the teriparatide-treated cohort and the matched control group (included for renal function context) are summarized in Table 1. The two groups were well matched for age, sex, and transplanted organ, reflecting the predefined matching strategy. Table 1Baseline characteristics: teriparatide and control groupTeriparatide (n = 39)Control (n = 39)Age (years), mean ± stdev (median)61.3 ± 11.6 (63)61.1 ± 11.2 (63)Sex, n (%)Male 13 (33%)Female 26 (67%)Male 13 (33%)Female 26 (67%)Organ transplantedKidney n = 10Lung n = 20Liver n = 9Heart n = 0Kidney n = 10Lung n = 20Liver n = 9Heart n = 0Previous fracture, n (%)35 (90%)8 (18%)Multiple fractures, n (%)31 (79%)5 (13%)BMD T score ≤ (−2.5), n (%)25/36 (69%)15/30 (50%)Previous treatment for osteoporosis, n (%)Oral bisphosphonatesZoledronic acidDenosumabRomosozumabNone23 (59%)5 (13%)2 (5%)0 (0%)14 (36%)14 (36%)1 (3%)4 (10%)a1 (3%)20 (51%)Anti-rejection drugs, n (%)SteroidsCNImTOR inhibitors39 (100%)38 (97%)2 (5%)32 (82%)36 (92%)2 (5%)Diabetes mellitus, n (%)15 (38%)22 (56%)Nephrolithiasis, n (%)1 (3%)2 (5%)Corrected calcium (mg/dL)Vitamin D (nmol/L)9.1 ± 1.166.8 ± 23.29.5 ± 0.657.1 ± 25.5BMD bone mineral density, CNI calcineurin inhibitors, mTOR mechanistic target of rapamycinaOne patient had been treated with oral bisphosphonates before denosumab therapy Table 1Baseline characteristics: teriparatide and control groupTeriparatide (n = 39)Control (n = 39)Age (years), mean ± stdev (median)61.3 ± 11.6 (63)61.1 ± 11.2 (63)Sex, n (%)Male 13 (33%)Female 26 (67%)Male 13 (33%)Female 26 (67%)Organ transplantedKidney n = 10Lung n = 20Liver n = 9Heart n = 0Kidney n = 10Lung n = 20Liver n = 9Heart n = 0Previous fracture, n (%)35 (90%)8 (18%)Multiple fractures, n (%)31 (79%)5 (13%)BMD T score ≤ (−2.5), n (%)25/36 (69%)15/30 (50%)Previous treatment for osteoporosis, n (%)Oral bisphosphonatesZoledronic acidDenosumabRomosozumabNone23 (59%)5 (13%)2 (5%)0 (0%)14 (36%)14 (36%)1 (3%)4 (10%)a1 (3%)20 (51%)Anti-rejection drugs, n (%)SteroidsCNImTOR inhibitors39 (100%)38 (97%)2 (5%)32 (82%)36 (92%)2 (5%)Diabetes mellitus, n (%)15 (38%)22 (56%)Nephrolithiasis, n (%)1 (3%)2 (5%)Corrected calcium (mg/dL)Vitamin D (nmol/L)9.1 ± 1.166.8 ± 23.29.5 ± 0.657.1 ± 25.5BMD bone mineral density, CNI calcineurin inhibitors, mTOR mechanistic target of rapamycinaOne patient had been treated with oral bisphosphonates before denosumab therapy Baseline characteristics: teriparatide and control group Male 13 (33%) Female 26 (67%) Male 13 (33%) Female 26 (67%) Kidney n = 10 Lung n = 20 Liver n = 9 Heart n = 0 Kidney n = 10 Lung n = 20 Liver n = 9 Heart n = 0 Oral bisphosphonates Zoledronic acid Denosumab Romosozumab None 23 (59%) 5 (13%) 2 (5%) 0 (0%) 14 (36%) 14 (36%) 1 (3%) 4 (10%)a 1 (3%) 20 (51%) Steroids CNI mTOR inhibitors 39 (100%) 38 (97%) 2 (5%) 32 (82%) 36 (92%) 2 (5%) Corrected calcium (mg/dL) Vitamin D (nmol/L) 9.1 ± 1.1 66.8 ± 23.2 9.5 ± 0.6 57.1 ± 25.5 BMD bone mineral density, CNI calcineurin inhibitors, mTOR mechanistic target of rapamycin aOne patient had been treated with oral bisphosphonates before denosumab therapy As expected, the teriparatide-treated group differed substantially from controls in clinical characteristics, consistent with treatment selection based on disease severity. Patients receiving teriparatide had a markedly higher prevalence of prior fragility fractures (90% vs 18%) and multiple fractures (79% vs 13%), as well as a higher proportion of osteoporotic-range BMD (69% vs 50%). Prior use of anti-osteoporotic therapy was also more common in the teriparatide group. These differences confirm that the treated cohort represents a selected high-risk population with more advanced skeletal disease compared with untreated transplant recipients. Teriparatide exposure Clinical and biochemical characteristics of the teriparatide-treated cohort at treatment initiation and at the end of therapy are summarized in Table 2. Teriparatide therapy was initiated at variable time points after transplantation, with a median interval of 36 months (IQR 15–102, mean 73 ± 94 months). Treatment duration was also variable, with a median of 22.3 months (range 3.1–25.3), reflecting real-world clinical practice rather than a predefined treatment protocol. Table 2Clinical and biochemical characteristics of patients treated with teriparatideTeriparatide group (n = 39)At start of treatmentEnd of treatmentOsteoporosis risk factors, n (%)Diabetes mellitusMenopauseMale hypogonadismSmokingBMI, kg/m215 (38%)22 (85%)5 (38%)1 (3%)25.0 ± 4.2Hypoparathyroidism, n (%)3 (8%)Calcium supplement, n (%)31 (79%)Vitamin D supplement, n (%)37 (95%)Fragility fractures, n (%)Prior fractures (before teriparatide therapy)35 (90%)Incident fractures (after the initiation of teriparatide)6 (17%)BMD T score ≤ (−2.5), n (%)Lumbar spineFemoral neckTotal hip17/33 (52%)22/36 (61%)12/19 (63%)6/20 (30%)9/22 (41%)8/18 (44%)Corrected calcium (mg/dL)Phosphorus (mg/dL)Vitamin D (nmol/L)Uric acid (mg/dL)Urine calcium (mg/day)9.1 ± 1.13.8 ± 0.666.8 ± 23.25.6 ± 1.5124.0 ± 91.49.3 ± 1.23.3 ± 0.776.3 ± 24.96.5 ± 1.398.6 ± 55.4BMD bone mineral density, ND not available/not systematically collected Table 2Clinical and biochemical characteristics of patients treated with teriparatideTeriparatide group (n = 39)At start of treatmentEnd of treatmentOsteoporosis risk factors, n (%)Diabetes mellitusMenopauseMale hypogonadismSmokingBMI, kg/m215 (38%)22 (85%)5 (38%)1 (3%)25.0 ± 4.2Hypoparathyroidism, n (%)3 (8%)Calcium supplement, n (%)31 (79%)Vitamin D supplement, n (%)37 (95%)Fragility fractures, n (%)Prior fractures (before teriparatide therapy)35 (90%)Incident fractures (after the initiation of teriparatide)6 (17%)BMD T score ≤ (−2.5), n (%)Lumbar spineFemoral neckTotal hip17/33 (52%)22/36 (61%)12/19 (63%)6/20 (30%)9/22 (41%)8/18 (44%)Corrected calcium (mg/dL)Phosphorus (mg/dL)Vitamin D (nmol/L)Uric acid (mg/dL)Urine calcium (mg/day)9.1 ± 1.13.8 ± 0.666.8 ± 23.25.6 ± 1.5124.0 ± 91.49.3 ± 1.23.3 ± 0.776.3 ± 24.96.5 ± 1.398.6 ± 55.4BMD bone mineral density, ND not available/not systematically collected Clinical and biochemical characteristics of patients treated with teriparatide Diabetes mellitus Menopause Male hypogonadism Smoking BMI, kg/m2 15 (38%) 22 (85%) 5 (38%) 1 (3%) 25.0 ± 4.2 Prior fractures (before teriparatide therapy) 35 (90%) Incident fractures (after the initiation of teriparatide) 6 (17%) Lumbar spine Femoral neck Total hip 17/33 (52%) 22/36 (61%) 12/19 (63%) 6/20 (30%) 9/22 (41%) 8/18 (44%) Corrected calcium (mg/dL) Phosphorus (mg/dL) Vitamin D (nmol/L) Uric acid (mg/dL) Urine calcium (mg/day) 9.1 ± 1.1 3.8 ± 0.6 66.8 ± 23.2 5.6 ± 1.5 124.0 ± 91.4 9.3 ± 1.2 3.3 ± 0.7 76.3 ± 24.9 6.5 ± 1.3 98.6 ± 55.4 BMD bone mineral density, ND not available/not systematically collected Teriparatide was used as first-line osteoporosis therapy in 36% of patients, while the remainder had received prior antiresorptive treatment, most commonly oral bisphosphonates (59%) or zoledronic acid (13%). The average follow-up since the start of teriparatide was 6.8 years. Concomitant calcium and vitamin D supplementation was prescribed in 79% and 95% of patients, respectively. All patients were receiving glucocorticoids at teriparatide initiation (mean daily dose of 7.0 ± 3.6 mg). Skeletal outcomes Six patients sustained fractures after initiation of teriparatide therapy; detailed characteristics are shown in Online Resource 1. Importantly, only two fractures occurred during active teriparatide treatment, whereas four fractures occurred after treatment discontinuation, with variable latency ranging from 4 months to more than 10 years after cessation. Among patients with appropriately paired DXA measurements at treatment initiation and completion, BMD data were available for 18 (46%), 17 (44%), and 11 (28%) patients at the lumbar spine, femoral neck, and total hip, respectively. In this subset, significant increases in BMD were observed at all evaluated skeletal sites. Lumbar spine BMD increased by 11 ± 15% (p = 0.01), femoral neck BMD by 8 ± 14% (p = 0.05), and total hip BMD by 11 ± 16% (p = 0.05) (Fig. 1).Fig. 1Changes in bone mineral density during teriparatide therapy in solid organ transplant recipients. Bone mineral density (g/cm2) at the lumbar spine, femoral neck, and total hip measured by dual-energy X-ray absorptiometry in patients with paired measurements at initiation (white bars) and completion (black bars) of teriparatide therapy. Data are shown for the subset of patients with available paired measurements (lumbar spine n = 18, femoral neck n = 17, total hip n = 11). Significant increases were observed at all skeletal sites Changes in bone mineral density during teriparatide therapy in solid organ transplant recipients. Bone mineral density (g/cm2) at the lumbar spine, femoral neck, and total hip measured by dual-energy X-ray absorptiometry in patients with paired measurements at initiation (white bars) and completion (black bars) of teriparatide therapy. Data are shown for the subset of patients with available paired measurements (lumbar spine n = 18, femoral neck n = 17, total hip n = 11). Significant increases were observed at all skeletal sites Biochemical and renal safety Changes in biochemical parameters during teriparatide therapy are summarized in Table 2. Hypercalcemia occurred in one patient (corrected calcium increased from 9.6 to 10.9 mg/dL during the second year of therapy), leading to teriparatide discontinuation. No cases of hypercalciuria were detected. Mean eGFR declined modestly during the first 6 months of teriparatide therapy (from 73 ± 31 to 64 ± 26 mL/min/1.73 m2) and remained stable thereafter, including after treatment discontinuation (62 ± 27 mL/min/1.73 m2 at 3–6 months post-therapy) (Table 3, Fig. 2). Repeated-measures ANOVA demonstrated a significant change in eGFR over time, driven by an early decline from baseline followed by stabilization during continued treatment and post-treatment follow-up (p < 0.001). Importantly, a similar magnitude of eGFR decline was observed in a contemporaneous matched control group of transplant recipients not treated with teriparatide (Fig. 2). Table 3Kidney function over timeBaseline6 months2 years3–6 months after end of teriparatideCreatinineControlTeriparatideSignificancea1.0 ± 0.31.0 ± 0.3p = 0.7831.1 ± 0.51.1 ± 0.4p = 0.7341.2 ± 0.61.2 ± 0.5p = 0.5281.1 ± 0.4Estimated GFR ControlTeriparatideSignificancea69 ± 2673 ± 31p = 0.63366 ± 29b64 ± 26bp = 0.62665 ± 3261 ± 25p = 0.50562 ± 27Estimated GFR—change from BaselineControlTeriparatideSignificancea−3 ± 17−9 ± 18p = 0.115−4 ± 17−13 ± 21p = 0.056−12 ± 20GFR glomerular filtration rateaSignificance—comparison between control and teriparatide at the same time pointbp < 0.05 for result at 6 months compared to result at baselineFig. 2Longitudinal kidney function in transplant recipients treated with teriparatide compared with untreated controls. Estimated glomerular filtration rate (eGFR) over time in teriparatide-treated transplant recipients (dashed line) and untreated controls (solid line), showing an early modest decline followed by stabilization over time in both groups Table 3Kidney function over timeBaseline6 months2 years3–6 months after end of teriparatideCreatinineControlTeriparatideSignificancea1.0 ± 0.31.0 ± 0.3p = 0.7831.1 ± 0.51.1 ± 0.4p = 0.7341.2 ± 0.61.2 ± 0.5p = 0.5281.1 ± 0.4Estimated GFR ControlTeriparatideSignificancea69 ± 2673 ± 31p = 0.63366 ± 29b64 ± 26bp = 0.62665 ± 3261 ± 25p = 0.50562 ± 27Estimated GFR—change from BaselineControlTeriparatideSignificancea−3 ± 17−9 ± 18p = 0.115−4 ± 17−13 ± 21p = 0.056−12 ± 20GFR glomerular filtration rateaSignificance—comparison between control and teriparatide at the same time pointbp < 0.05 for result at 6 months compared to result at baseline Kidney function over time Control Teriparatide Significancea 1.0 ± 0.3 1.0 ± 0.3 p = 0.783 1.1 ± 0.5 1.1 ± 0.4 p = 0.734 1.2 ± 0.6 1.2 ± 0.5 p = 0.528 Control Teriparatide Significancea 69 ± 26 73 ± 31 p = 0.633 66 ± 29b 64 ± 26b p = 0.626 65 ± 32 61 ± 25 p = 0.505 Control Teriparatide Significancea −3 ± 17 −9 ± 18 p = 0.115 −4 ± 17 −13 ± 21 p = 0.056 GFR glomerular filtration rate aSignificance—comparison between control and teriparatide at the same time point bp < 0.05 for result at 6 months compared to result at baseline Longitudinal kidney function in transplant recipients treated with teriparatide compared with untreated controls. Estimated glomerular filtration rate (eGFR) over time in teriparatide-treated transplant recipients (dashed line) and untreated controls (solid line), showing an early modest decline followed by stabilization over time in both groups Five patients experienced a decline in eGFR to < 30 mL/min/1.73 m2 during follow-up; all had baseline eGFR values between 30 and 39 mL/min/1.73 m2. Only one patient discontinued teriparatide after 8 months of treatment. No patient progressed to end-stage kidney disease or required renal replacement therapy. Other adverse events Five patients reported non-renal adverse events, including myalgia (n = 2), nausea (n = 2), and dizziness (n = 1). Twenty-one patients were hospitalized during teriparatide therapy, most commonly due to infections (n = 9). No episodes of graft rejection occurred during treatment. Nine patients died during study follow-up, including seven deaths within the first 2 years of teriparatide initiation; deaths were attributed to underlying comorbidities rather than treatment-related causes. Sex-based analyses Sex-stratified analyses are presented in Table 4. Age, fracture history, treatment duration, and baseline BMD did not differ between women and men. Diabetes mellitus was significantly more prevalent among male recipients (70% vs 23%, p = 0.01). Table 4Comparison between male and female subjectsFemale (n = 26)Male (n = 13)Age (years), mean ± stdev62.3 ± 11.659.2 ± 11.8p = 0.44Organ transplantedKidney n = 8Lung n = 12Liver n = 6Heart n = 0Kidney n = 2Lung n = 8Liver n = 3Heart n = 0p = 0.51Duration of teriparatide therapy (months), median (min, max)21.5 (3.1, 25.3)23.8 (6.1, 24.7)p = 0.35Previous fracture, n (%)23 (88%)12 (92%)p = 0.71Multiple fractures, n (%)19 (73%)12 (92%)p = 0.16Previous treatment for osteoporosis, n (%)MHT/SERM/testosteroneOral bisphosphonatesZoledronic acidDenosumabNone14 (54%)15 (58%)5 (19%)2 (8%)9 (35%)0 (0%)8 (62%)0 (0%)0 (0%)5 (38%)N/Ap = 0.82N/AN/Ap = 0.81Calcium supplement, n (%)20 (77%)10 (77%)p = 1.00Vitamin D supplement, n (%)25 (96%)25 (92%)p = 0.35Anti-rejection drugs, n (%)SteroidsCNImTOR inhibitors26 (100%)25 (96%)2 (8%)13 (100%)13 (100%)0 (0%)N/AN/AN/ARisk factors for decreased bone density, n (%)Diabetes mellitusMenopauseMale hypogonadismSmokingBMI, kg/m2, mean ± stdev6 (23%)22 (85%)N/A1 (4%)25.0 ± 4.89 (70%)N/A5 (38%)0 (0%)24.6 ± 3.5p = 0.01N/AN/AN/Ap = 0.77Nephrolithiasis, n (%)0 (0%)1 (8%)N/AHypoparathyroidism, n (%)3 (12%)0 (0%)N/ABMD T score ≤ (−2.5), n (%)Lumbar spineFemoral neckTotal hip12 (46%)16 (62%)10 (38%)5 (38%)5 (38%)2 (15%)p = 0.21p = 0.17p = 0.14Baseline labs, mean ± stdevCorrected calcium (mg/dL)Phosphorus (mg/dL)Creatinine (mg/dL)eGFR (mL/min/1.732)Vitamin D (nmol/L)Urine calcium (mg/day)9.2 ± 0.63.9 ± 0.71.0 ± 0.365 ± 2363 ± 1790 ± 549.2 ± 0.53.5 ± 0.41.0 ± 0.389 ± 3975 ± 30173 ± 119p = 0.91p = 0.04p = 0.95p = 0.06p = 0.16p = 0.09eGFR on teriparatide (at 6 months of therapy)59 ± 2474 ± 27p = 0.10eGFR at end of teriparatide54 ± 2274 ± 27p = 0.03eGFR 3–6 months after stop of teriparatide58 ± 2775 ± 26p = 0.10Change in eGFR on teriparatidea−6−14p = 0.25Change in eGFR after stop of teriparatidea−7−14p = 0.53MHT menopausal hormone therapy, SERM selective estrogen receptor modulator, CNI calcineurin inhibitors, mTOR mechanistic target of rapamycin, BMI body mass index, BMD bone mineral density, eGFR estimated glomerular filtration rateaCompared to baseline eGFR Table 4Comparison between male and female subjectsFemale (n = 26)Male (n = 13)Age (years), mean ± stdev62.3 ± 11.659.2 ± 11.8p = 0.44Organ transplantedKidney n = 8Lung n = 12Liver n = 6Heart n = 0Kidney n = 2Lung n = 8Liver n = 3Heart n = 0p = 0.51Duration of teriparatide therapy (months), median (min, max)21.5 (3.1, 25.3)23.8 (6.1, 24.7)p = 0.35Previous fracture, n (%)23 (88%)12 (92%)p = 0.71Multiple fractures, n (%)19 (73%)12 (92%)p = 0.16Previous treatment for osteoporosis, n (%)MHT/SERM/testosteroneOral bisphosphonatesZoledronic acidDenosumabNone14 (54%)15 (58%)5 (19%)2 (8%)9 (35%)0 (0%)8 (62%)0 (0%)0 (0%)5 (38%)N/Ap = 0.82N/AN/Ap = 0.81Calcium supplement, n (%)20 (77%)10 (77%)p = 1.00Vitamin D supplement, n (%)25 (96%)25 (92%)p = 0.35Anti-rejection drugs, n (%)SteroidsCNImTOR inhibitors26 (100%)25 (96%)2 (8%)13 (100%)13 (100%)0 (0%)N/AN/AN/ARisk factors for decreased bone density, n (%)Diabetes mellitusMenopauseMale hypogonadismSmokingBMI, kg/m2, mean ± stdev6 (23%)22 (85%)N/A1 (4%)25.0 ± 4.89 (70%)N/A5 (38%)0 (0%)24.6 ± 3.5p = 0.01N/AN/AN/Ap = 0.77Nephrolithiasis, n (%)0 (0%)1 (8%)N/AHypoparathyroidism, n (%)3 (12%)0 (0%)N/ABMD T score ≤ (−2.5), n (%)Lumbar spineFemoral neckTotal hip12 (46%)16 (62%)10 (38%)5 (38%)5 (38%)2 (15%)p = 0.21p = 0.17p = 0.14Baseline labs, mean ± stdevCorrected calcium (mg/dL)Phosphorus (mg/dL)Creatinine (mg/dL)eGFR (mL/min/1.732)Vitamin D (nmol/L)Urine calcium (mg/day)9.2 ± 0.63.9 ± 0.71.0 ± 0.365 ± 2363 ± 1790 ± 549.2 ± 0.53.5 ± 0.41.0 ± 0.389 ± 3975 ± 30173 ± 119p = 0.91p = 0.04p = 0.95p = 0.06p = 0.16p = 0.09eGFR on teriparatide (at 6 months of therapy)59 ± 2474 ± 27p = 0.10eGFR at end of teriparatide54 ± 2274 ± 27p = 0.03eGFR 3–6 months after stop of teriparatide58 ± 2775 ± 26p = 0.10Change in eGFR on teriparatidea−6−14p = 0.25Change in eGFR after stop of teriparatidea−7−14p = 0.53MHT menopausal hormone therapy, SERM selective estrogen receptor modulator, CNI calcineurin inhibitors, mTOR mechanistic target of rapamycin, BMI body mass index, BMD bone mineral density, eGFR estimated glomerular filtration rateaCompared to baseline eGFR Comparison between male and female subjects Kidney n = 8 Lung n = 12 Liver n = 6 Heart n = 0 Kidney n = 2 Lung n = 8 Liver n = 3 Heart n = 0 MHT/SERM/testosterone Oral bisphosphonates Zoledronic acid Denosumab None 14 (54%) 15 (58%) 5 (19%) 2 (8%) 9 (35%) 0 (0%) 8 (62%) 0 (0%) 0 (0%) 5 (38%) N/A p = 0.82 N/A N/A p = 0.81 Anti-rejection drugs, n (%) Steroids CNI mTOR inhibitors 26 (100%) 25 (96%) 2 (8%) 13 (100%) 13 (100%) 0 (0%) N/A N/A N/A Diabetes mellitus Menopause Male hypogonadism Smoking BMI, kg/m2, mean ± stdev 6 (23%) 22 (85%) N/A 1 (4%) 25.0 ± 4.8 9 (70%) N/A 5 (38%) 0 (0%) 24.6 ± 3.5 p = 0.01 N/A N/A N/A p = 0.77 BMD T score ≤ (−2.5), n (%) Lumbar spine Femoral neck Total hip 12 (46%) 16 (62%) 10 (38%) 5 (38%) 5 (38%) 2 (15%) p = 0.21 p = 0.17 p = 0.14 Corrected calcium (mg/dL) Phosphorus (mg/dL) Creatinine (mg/dL) eGFR (mL/min/1.732) Vitamin D (nmol/L) Urine calcium (mg/day) 9.2 ± 0.6 3.9 ± 0.7 1.0 ± 0.3 65 ± 23 63 ± 17 90 ± 54 9.2 ± 0.5 3.5 ± 0.4 1.0 ± 0.3 89 ± 39 75 ± 30 173 ± 119 p = 0.91 p = 0.04 p = 0.95 p = 0.06 p = 0.16 p = 0.09 MHT menopausal hormone therapy, SERM selective estrogen receptor modulator, CNI calcineurin inhibitors, mTOR mechanistic target of rapamycin, BMI body mass index, BMD bone mineral density, eGFR estimated glomerular filtration rate aCompared to baseline eGFR Baseline eGFR was higher in men, as well as at the end of teriparatide therapy. However, the magnitude of eGFR change during and after teriparatide treatment did not differ significantly between sexes. Discussion In this single-center retrospective cohort, we report one of the largest and most heterogeneous real-world cohorts of SOT recipients with osteoporosis treated with teriparatide. Our findings demonstrate that teriparatide treatment was associated with clinically meaningful improvements in bone mineral density at the lumbar spine and hip in this selected high-risk cohort, accompanied by a low incidence of treatment-limiting adverse effects and no apparent increase in graft-related complications. These findings support the potential role of anabolic therapy in carefully selected transplant recipients with severe osteoporosis. Importantly, the comparison with untreated transplant recipients highlights the strong selection inherent to teriparatide use in clinical practice. Despite matching for demographic and transplant-related variables, treated patients had substantially more severe skeletal disease at baseline, including a markedly higher burden of prior fractures and lower bone density (Table 1). This reflects appropriate clinical decision-making and reimbursement constraints but limits direct comparison between groups and precludes causal inference regarding treatment effects. Although teriparatide is an established first-line therapy for glucocorticoid-induced osteoporosis, its effectiveness in transplant recipients remains uncertain. Concerns have been raised regarding potential skeletal resistance to parathyroid hormone after transplantation, attributed to adynamic bone disease and the cumulative effects of long-term immunosuppressive therapy. Both experimental and clinical studies have suggested impaired osteoblastic responsiveness to PTH signaling in chronic kidney disease and post-transplant states [17, 18], thereby questioning the anabolic efficacy of teriparatide in this population. However, evidence directly addressing these concerns in transplant recipients remains limited. Notably, most published experience with teriparatide in transplant recipients relates to its use for refractory hypocalcemia due to hypoparathyroidism [19–22], particularly after parathyroidectomy, rather than for osteoporosis treatment. These reports primarily focus on biochemical correction, with limited assessment of skeletal outcomes. Only a small number of case reports, small series, or retrospective studies have evaluated the bone effects of teriparatide for osteoporosis, describing modest increases in bone mineral density in lung [11, 14] and kidney [13, 15] transplant recipients and histological evidence of increased bone formation in a heart transplant patient with low-turnover bone disease [12]. Overall, data on the skeletal efficacy of teriparatide in transplant populations remain sparse and largely anecdotal. To date, there is only one randomized controlled trial on teriparatide use in transplant recipients, conducted by Cejka et al. [10]. The trial evaluated teriparatide initiated early after kidney transplantation for 6 months and did not demonstrate improvements in bone mineral density or histomorphometric parameters. Importantly, therapy in that study was started during a period characterized by intense immunosuppression, high-dose glucocorticoid exposure, and markedly suppressed bone turnover, and treatment duration was relatively short. These factors likely limited the ability to detect meaningful structural skeletal responses. Notably, despite the absence of BMD improvement, bone loss was prevented in the teriparatide group compared with placebo, suggesting a possible protective effect during the early post-transplant period. In contrast, patients in our cohort initiated teriparatide later after transplantation (similar to other retrospective studies [13–15], see Table 5) and were treated for a median duration exceeding 22 months, reflecting real-world clinical practice in which anabolic therapy is typically considered after stabilization of graft function and immunosuppressive regimens. This later timing, combined with longer exposure, may explain the substantial BMD gains observed in our study. The magnitude of improvement, approximately 11% at the lumbar spine and 8–11% at the hip, is comparable to responses reported in non-transplant populations and exceeds those typically achieved with antiresorptive therapy in transplant recipients. These changes were observed in analyses restricted to patients with paired measurements at treatment initiation and completion and were accompanied by a reduction in the proportion of patients with osteoporotic-range BMD across skeletal sites (Table 2). Table 5Teriparatide use in solid organ transplant recipients: comparison of published evidenceStudyAge mean (yr)Sex (male)PopulationDesignN (TP)Mean time after transplant (months)Duration (median, months)BMD outcomeFracturesKidney safetyCurrent study61 ± 1233%Kidney, lung, liver, heartRetrospective3973 ± 94 (median 36 mo)22.3 (3.1–25.3)↑ LS, FN, TH2 during active therapy; 4 after treatment discontinuationEarly ↓ then stable eGFRCejka (2008)51 ± 975%KidneyRCT (vs placebo)12:12 ≥ 16 moStable BMD vs ↓placeboNRStableQiu (2021)47 ± 729%KidneyRetrospective6861 ± 1212 mo↑ LS, FN, TH↑ vs alendronate1 (colles):5 (3 vert + 2nonvert)StableVetrano (2025)64 ± 856%KidneyRetrospective, single center1867 ± 912 mo (all pts) to 24 mo (9 pts)↑ LS, TH1 (AE)StableJanuary (2025)60 ± 239%LungComparative cohort (vs alendronate, denosumab)4435 ± 1515.6 mo (6.0–25.2)↑ LS, hip (vs alendronate)18% (similar to other groups)StableTP teriparatide, RCT randomized control study, BMD bone mineral density, LS lumbar spine, FN femoral neck, TH total hip Table 5Teriparatide use in solid organ transplant recipients: comparison of published evidenceStudyAge mean (yr)Sex (male)PopulationDesignN (TP)Mean time after transplant (months)Duration (median, months)BMD outcomeFracturesKidney safetyCurrent study61 ± 1233%Kidney, lung, liver, heartRetrospective3973 ± 94 (median 36 mo)22.3 (3.1–25.3)↑ LS, FN, TH2 during active therapy; 4 after treatment discontinuationEarly ↓ then stable eGFRCejka (2008)51 ± 975%KidneyRCT (vs placebo)12:12 ≥ 16 moStable BMD vs ↓placeboNRStableQiu (2021)47 ± 729%KidneyRetrospective6861 ± 1212 mo↑ LS, FN, TH↑ vs alendronate1 (colles):5 (3 vert + 2nonvert)StableVetrano (2025)64 ± 856%KidneyRetrospective, single center1867 ± 912 mo (all pts) to 24 mo (9 pts)↑ LS, TH1 (AE)StableJanuary (2025)60 ± 239%LungComparative cohort (vs alendronate, denosumab)4435 ± 1515.6 mo (6.0–25.2)↑ LS, hip (vs alendronate)18% (similar to other groups)StableTP teriparatide, RCT randomized control study, BMD bone mineral density, LS lumbar spine, FN femoral neck, TH total hip Teriparatide use in solid organ transplant recipients: comparison of published evidence ↑ LS, FN, TH ↑ vs alendronate TP teriparatide, RCT randomized control study, BMD bone mineral density, LS lumbar spine, FN femoral neck, TH total hip Our findings are consistent with results from recent observational studies in kidney transplant recipients. Qiu et al. demonstrated greater increases in lumbar spine and hip BMD with teriparatide compared with alendronate over 12 months [13], while Vetrano et al. reported significant BMD gains in patients with low bone turnover disease treated with teriparatide in a multicenter Italian experience [15]. Importantly, unlike previous studies restricted to kidney transplantation, our cohort included kidney, lung, and liver transplant recipients, thereby extending the potential applicability of anabolic therapy across multiple transplant populations. Fracture outcomes in transplant cohorts are challenging to interpret due to severe baseline skeletal disease and limited event numbers. In our study, although fractures occurred in a minority of patients during teriparatide exposure, these events were largely observed in individuals with extremely high baseline fracture burden and advanced osteoporosis. Given the retrospective design, lack of an untreated comparator, and limited fracture event numbers, our study was not powered to detect a fracture-reduction signal. Nevertheless, the stabilization of fracture incidence in a cohort with severe baseline skeletal fragility is clinically reassuring and consistent with fracture trends reported in other transplant series [14]. A key concern limiting the use of osteoporotic therapy in transplant recipients is renal safety. In our cohort, eGFR declined modestly during the first 6 months of teriparatide therapy but subsequently stabilized, including after treatment discontinuation. Importantly, a broadly similar pattern of kidney function change was observed in contemporaneous matched transplant controls not treated with teriparatide. Because the study was not designed or powered to formally compare renal outcomes between groups, and because treated patients represented a clinically selected high-risk population, definitive conclusions regarding the renal effects of teriparatide cannot be drawn. However, no clear signal of accelerated kidney function decline was observed. No patient progressed to end-stage kidney disease or required dialysis during teriparatide treatment or follow-up. Metabolic adverse events were infrequent. Hypercalcemia occurred in only one patient and resolved with treatment discontinuation. This is consistent with previous reports in transplant recipients [19]. Despite widespread concomitant calcium and vitamin D supplementation, no cases of clinically significant hypercalciuria were observed. These findings are consistent with prior reports and support the metabolic safety of teriparatide in transplant populations when appropriately monitored. Adverse events were generally mild and consistent with the known safety profile of teriparatide, including musculoskeletal pain, nausea, and dizziness. Treatment discontinuation due to adverse effects was uncommon, reinforcing the tolerability of teriparatide even with prolonged exposure. Taken together, our findings suggest that teriparatide represents a viable therapeutic option for selected solid organ transplant recipients with severe osteoporosis. While not suitable for universal use, teriparatide may fill a critical treatment gap in high-risk transplant populations where antiresorptive therapy is ineffective or contraindicated. This study has several strengths and limitations. The retrospective design, absence of a homogeneous control group, and heterogeneity of transplant types limit causal inference. In addition, treatment allocation was not protocol-driven but based on clinical judgment and influenced by national reimbursement policies, resulting in a selected high-risk population enriched for patients with severe or glucocorticoid-induced osteoporosis and introducing potential indication bias. Variability in the timing of treatment initiation and duration further reflects real-world practice but introduces additional heterogeneity. Although a matched contemporaneous control group was included, it was designed solely for contextual comparison of renal function and not for comparative effectiveness analyses, and substantial baseline differences in skeletal risk remained. BMD analyses were restricted to patients with paired measurements aligned with treatment initiation and completion, which reduced sample size but improved internal validity by ensuring that observed changes reflected the treatment period. Bone turnover markers and histomorphometric data were not systematically available, precluding mechanistic insights into anabolic responsiveness. Residual confounding by disease severity and survivor bias cannot be excluded. Nonetheless, the relatively large cohort, extended follow-up, and inclusion of clinically relevant skeletal and safety outcomes distinguish this study from prior reports. In conclusion, in this large real-world cohort of solid organ transplant recipients, teriparatide therapy was associated with clinically meaningful improvements in bone mineral density, acceptable metabolic and renal safety, and no apparent excess risk to graft function. These findings support the selective use of anabolic therapy in transplant recipients with severe osteoporosis and highlight the need for prospective studies to define optimal patient selection, treatment timing, and sequencing strategies in this complex population. Supplementary Information Below is the link to the electronic supplementary material.ESM 1(PDF 78.7 KB) (PDF 78.7 KB)